These links are provided for information only. NPPG is not responsible for the content of any link
April 2020
- COVID-19 rapid guideline: severe asthma – guidance (NG166)
- National Patient Safety Alert: Interruption of high flow nasal oxygen during transfer
March 2020
- Paediatric to adult transition care for patients with sickle cell disease: a global perspective
- COVID-19: guidance on supporting children and young people’s mental health and wellbeing
- COVID-19 infection in children
- CHMP recommends licence extension for etravirine (Intelence)
- CHMP recommends licence extension for conestat alfa (Ruconest)
- US FDA accepts New Drug Application (NDA) for new formulation of baloxavir for the treatment of influenza in children
- Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
- Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn
- Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies
- Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study
- SARS-CoV-2 Infection in Children
- February BNF/BNFC newsletter
- Selumetinib in Children with Inoperable Plexiform Neurofibromas
- Clinical Commissioning Policy: Human coagulation factor X for hereditary factor X deficiency (all ages)
- Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
- Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Clinical Commissioning Policy: Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)
- Revised SPC: Dioralyte products
- New product: Adynovi (rurioctocog alfa pegol) 1000 IU powder and solvent for solution for injection 2 ml solvent
- Cardiovascular Health Trajectories From Childhood Through Middle Age and Their Association With Subclinical Atherosclerosis
- Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
- Clinical Commissioning Policy: Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Bronchiolitis: when less is more
- Import restrictions changed for cannabis-based medicines to allow faster access
- Ensuring access to safe, effective, and affordable cannabis‐based medicines
- State of Child Health in the UK
- FDA Grants rare paediatric disease designation for elamipretide for Barth Syndrome
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine Prophylaxis A Systematic Review and Network Meta-analysis
- Canakinumab for Periodic Fever Syndromes in children to be commissioned by NHS England
February 2020
- Neonatal parenteral nutrition – guidance [NG154]
- Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study
- Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
- Plerixafor (Mozobil®) recommended for use within NHS Wales in combination with G-CSF
- New advances in the treatment of paediatric functional abdominal pain disorders
- Asthma: diagnosis, monitoring and chronic asthma management- updated guideline (NG80)
- Young people’s mental health and wellbeing research
- Refractory Epilepsy Specialist Clinical Advisory Service
- Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction
- A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents
- Lower versus Traditional Treatment Threshold for Neonatal Hypoglycemia
- US FDA approves Palforzia (Arachis hypogaea) Allergen Powder capsules for treatment of peanut allergy
January 2020
- Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of rituximab (MabThera) for paediatric patients
- Update on gender identity development service for children and young people
- First-Trimester Pregnancy Exposure to Modafinil and Risk of Congenital Malformations
- Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
- US FDA approved fidaxomicin oral suspension for clostridioides difficile-associated diarrhoea (CDAD) in children aged six months and older
- Assessing coverage of interventions for reproductive, maternal, newborn, child, and adolescent health and nutrition
- European Medicines Agency approves license extension for ustekinumab to include treatment of plaque psoriasis in children between 6 and 11 years
- Duchenne muscular dystrophy (DMD)
- Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
- January BNF/BNFC Newsletter
- Where next for inhaled corticosteroids in childhood asthma?
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
- Sodium valproate Pregnancy Prevention Programme – updated Guide for Healthcare Professionals
- A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
- Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort
- Precocious puberty
- Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy
- Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial
- Antiepileptic Drug Exposure in Infants of Breastfeeding Mothers With Epilepsy
- Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen
December 2019
- In use product safety assessment report for Alkindi (hydrocortisone) granules in capsules for opening
- Paediatric Intensive Care Audit Network: Annual Report 2019
- NICE Bites – Fever in under 5s
- European Paediatric Formulary of extemporaneous preparations goes live
- December BNF/BNFC Newsletter.
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
- Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome – guidance (TA615)
- Cannabidiol with clobazam for treating seizures associated with Dravet syndrome – guidance (TA614)
- Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
- Approval of licence extension for cystic fibrosis therapy ivacaftor (Kalydeco)
- Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
- Association Between Fertility Treatment and Cancer Risk in Children
- Summary of American Academy of Neurology guideline for acute treatment of migraine in children and adolescents and pharmacologic treatment for paediatric migraine prevention
- Does general anaesthesia affect neurodevelopment in infants and children?
- Revised SPC: Diovan 3 mg/ml Oral Solution (valsartan) – licensed for ages 1 to 6
- Clinical Commissioning Policy: Maternal intravenous immunoglobulin (IVIg) for the prevention of allo-immune fetal and neonatal haemochromatosis
- HPV: WHO calls for countries to suspend vaccination of boys
- National measles guidelines
November 2019
- General Pharmaceutical Council launches new guidance for pharmacist prescribers to ensure safe and effective prescribing
- Supply Disruption Alert: Emerade 150 microgram, 300 microgram and 500 microgram adrenaline auto-injector devices
- FDA approves Toujeo (insulin glargine) to treat childhood type 1 diabetes
- Educational Risk Minimisation Materials to help reduce the risk associated with using glycopyrronium bromide (Sialanar) 320 micrograms /ml Oral Solution
- November BNF/BNFC Newsletter
- Longitudinal, strain-specific Staphylococcus aureus introduction and transmission events in households of children with community-associated meticillin-resistant S aureus skin and soft tissue infection: a prospective cohort study
- Pre-school vaccinations: guide to vaccinations from 2 to 5 years
- Revised SPC: Qvar (beclometasone dipropionate) MDI – all strengths – pescribing information for 5 years and above
- Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study
- Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations
- School-based interventions to prevent anxiety and depression in children and young people: a systematic review and network meta-analysis
- Practical aspects of childhood epilepsy
- Flu-vaccine nasal spray delayed for some schoolchildren
- Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome – Final Appraisal Determination
- Urgent Policy Statement: Cystic Fibrosis Modulator Therapies
- Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
- Sanofi presents data from EDITION JUNIOR phase III trial of Toujeo (insulin glargine 300 Units/mL) vs. insulin glargine 100 Units/mL (Gla-100) in children and adolescents aged 6 to 17 years with type 1 diabetes
- NIHR Signals: Antimicrobial central venous catheters do not reduce infections in pre-term babies
- Fever in under 5s: assessment and initial management- guidance (NG143)
- Paediatric critical care and surgery in children review: Summary report
- Human and animal bites: antimicrobial prescribing – Draft guidance consultation
- Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial
- Immunisations: babies up to 13 months of age
- FDA statement on new testing results, including low levels of impurities in ranitidine drugs
- Narsoplimab receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan required for licensing application
- Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood
- Zanamivir (Dectova®)
- Belimumab licence extension for use in children from age 5 approved in the European Union
- BNF/BNFC newsletter October 2019
October 2019
- Investigation into pre-school vaccinations routinely provided in England in 2018/2019
- FDA approves license extension for Botulinum A toxin for treatment of lower limb spasticity in children and adolescents aged 2 to 17 years
- Perinatal Management of Extreme Preterm Birth before 27 weeks of gestation: A Framework for Practice
- Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial
- Incidence of anorexia nervosa in young people in the UK and Ireland: a national surveillance study
- Committee for Medicinal Products for Human Use (CHMP) recommends approval of Baqsimi (glucagon)
- Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort
- Letter to healthcare professionals regarding parenteral nutrition products for neonates and children below 2 years of age – protect from light
- Adrenaline auto-injectors: recent actions taken to support safety
- Differences in lung function between children with sickle cell anaemia from West Africa and Europe
- Duration of intravenous antibiotic therapy in people with cystic fibrosis
- NICE draft Quality Standard published for consultation: Specialist neonatal respiratory care for babies born preterm
- Band ligation versus beta‐blockers for primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
- Mandatory childhood vaccination could cause “irreparable damage,” says expert panel
- Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis
- Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
- Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
- Gastro-oesophageal reflux disease in children and young people: diagnosis and management – updated guidance (NG1)
- Fetal Alcohol Spectrum Disorder (FASD)
- New product: Epidyolex (cannabidiol) 100 mg/ml oral solution
- FDA accepts for review two New Drug Applications (NDAs) for fidaxomicin to treat children aged six months up to 18 years with Clostridium difficile infections
- Epilepsies: diagnosis and management- updated clinical guideline (CG137)
September 2019
- September 2019 BNF/BNFc newsletter
- US FDA approves Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids
- Pfizer announces positive results for abrocitinib in atopic dermatitis for patients 12 and older
- Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions
- Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
- Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for treatment of upper limb spasticity in children, excluding cerebral palsy
- DTB Commentary: Do oral steroids improve hearing outcomes in children with otitis media with effusion?
- TNF‐α blockers for the treatment of Kawasaki disease in children
- Childhood Vaccination Coverage Statistics – England 2018-19
- Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial
- Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
- European CHMP issues positive opinion for paediatric license extension of belimumab (Benlysta)
- Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis
- Pneumonia (hospital-acquired): antimicrobial prescribing- guideline [NG139]
- Sulthiame add‐on therapy for epilepsy
- Attention deficit hyperactivity disorder: diagnosis and management – updated guidance (NG87)
- UK immunisation schedule: the green book, chapter 11 updated
- FDA approves hydroxyprogesterone caproate (HPC) to prevent preterm birth
- Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
- Methylphenidate and stuttering
- Neonatal parenteral nutrition – draft guidance
- Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017
- Use of tumour necrosis factor-α inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in Denmark: a nationwide cohort study
- Twin and triplet pregnancy – guidance (NG137)
- NHS warning to parents as ‘asthma season’ hits
- August BNF/BNFC eNewsletter
- Vancomycin is commonly under‐dosed in critically ill children and neonates
- Revised SPCs: Strensiq (asfotase alfa) solution for injection (all strengths)
For older news click here